Previous studies demonstrated that dysplasia was not relevant for AML with CEBPA and RUNX1 mutations, and RAS pathway mutations and FLT3-ITD were significantly more frequent in cases without evaluable erythroid cells [25,26]. This evidence concerns the gene FLT3 and acute myeloid leukemia.